RusnanoMedInvest specializes in investing in the development of innovative pharmaceutical technologies and products in Russia and worldwide.
We are interested in investment opportunities in promising new developments in the field of pharmaceuticals and medical equipment;
Our investment strategy and focus centers primarily around projects at the later stages of development, in particular compounds or products that have proven, market-relevant differentiated therapeutic efficacy, tolerability or safety in phase 2 or later or otherwise demonstrate game-changing potential with respect to patient welfare or healthcare economics.
Our portfolio companies:
Clearside Biomedical, Inc. (Nasdaq:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced completion of enrollment of an exploratory clinical trial (the “HULK” trial) of CLS-TA for suprachoroidal administration, its proprietary suspension formulation of the corticosteroid triamcinolone acetonide, with or without intravitreal Eylea® (aflibercept), for the treatment of diabetic macular edema (“DME”).
11 April 2017
10 April 2017
05 April 2017